Korro Bio, Inc. (KRRO)
Data as of , from SEC Form 4 filings.
See up to 3 months of KRRO. The 7-day demo opens the 1M and 3M ranges and puts KRRO on your watchlist.
Start 7-day demoLatest KRRO insider trades
About Korro Bio, Inc. (KRRO)
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
- CAMBRIDGE, MA
- 57
- 2023
- XNAS
KRRO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 6,684 | $79K |
| Open-market sale | 14 | 92,761 | $1.28M |
| Grant or award | 4 | 27,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
KRRO insider transactions (Form 4)
5150 Form 4 filings on record, the earliest from Oct 18, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jean Francois Formela - Director | Open-market sale | Common Stock | 8,450 | $13.99 footnote F2 | $118K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 1,750 | $13.99 footnote F2 | $24K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 31,888 | $14.12 footnote F5 | $450K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 6,602 | $14.12 footnote F5 | $93K | |
| ||||||
| Oliver Dolan - Officer | Open-market sale | Common Stock | 5 | $13.72 footnote F2 | $69 | |
| ||||||
| Oliver Dolan - Officer | Open-market sale | Common Stock | 7,347 | $13.51 footnote F2 | $99K | |
| Oliver Dolan - Officer | Open-market sale | Common Stock | 6 | $13.60 footnote F4 | $82 | |
| ||||||
| Jean Francois Formela - Director | Open-market sale | Common Stock | 249 | $13.96 footnote F2 | $3K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 51 | $13.96 footnote F2 | $712 | |
| ||||||
| Jean Francois Formela - Director | Open-market sale | Common Stock | 23,584 | $14.00 footnote F2 | $330K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 4,884 | $14.00 footnote F2 | $68K | |
| ||||||
| Jean Francois Formela - Director | Open-market sale | Common Stock | 1,775 | $13.96 footnote F2 | $25K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 368 | $13.96 footnote F2 | $5K | |
| ||||||
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.001 par value per share | 5,222 | $11.40 footnote F2 | $60K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.001 par value per share | 1,462 | $13.19 footnote F3 | $19K | |
| ||||||
| Ram Aiyar - Officer | Open-market sale | Common Stock | 5,802 | $10.84 footnote F2 | $63K | |
| ||||||
| Loic A. Vincent - Officer | Grant or award | Common Stock | 7,500 footnote F1 | $0.00 | - | |
| ||||||
| Oliver Dolan - Officer | Grant or award | Common Stock | 5,500 footnote F1 | $0.00 | - | |
| ||||||
| Jeffrey Cerio - Officer | Grant or award | Common Stock | 6,500 footnote F1 | $0.00 | - | |
| ||||||
| Todd Chappell - Officer | Grant or award | Common Stock | 7,500 footnote F1 | $0.00 | - | |
| ||||||
| Jean Francois Formela | Open-market sale | Common Stock | 85,955 | $14.03 footnote F2 | $1.21M | |
| Jean Francois Formela | Open-market sale | Common Stock | 14,745 | $14.03 footnote F2 | $207K | |
| Jean Francois Formela | Open-market sale | Common Stock | 817 | $13.96 footnote F5 | $11K | |
| Jean Francois Formela | Open-market sale | Common Stock | 8,506 | $13.96 footnote F5 | $119K | |
| ||||||
| Jean Francois Formela | Open-market sale | Common Stock | 17,426 | $14.25 footnote F4 | $248K | |
| Jean Francois Formela | Open-market sale | Common Stock | 40,679 | $14.60 footnote F5 | $594K | |
| Jean Francois Formela | Open-market sale | Common Stock | 666 | $14.98 footnote F6 | $10K | |
| Jean Francois Formela | Open-market sale | Common Stock | 6,979 | $14.60 footnote F5 | $102K | |
| Jean Francois Formela | Open-market sale | Common Stock | 114 | $14.98 footnote F6 | $2K | |
| Jean Francois Formela | Open-market sale | Common Stock | 3,382 | $13.95 | $47K | |
| Jean Francois Formela | Open-market sale | Common Stock | 580 | $13.95 | $8K | |
| Jean Francois Formela | Open-market sale | Common Stock | 101,579 | $14.25 footnote F4 | $1.45M | |
| ||||||
| Todd Chappell - Officer | Open-market sale | Common Stock | 3,168 | $10.83 footnote F2 | $34K | |
| ||||||
| Loic A. Vincent - Officer | Open-market sale | Common Stock | 3,418 | $10.83 footnote F2 | $37K | |
| ||||||
| Jeffrey Cerio - Officer | Open-market sale | Common Stock | 6,609 | $10.83 footnote F2 | $72K | |
| ||||||
| Oliver Dolan - Officer | Open-market sale | Common Stock | 3,383 | $10.83 footnote F2 | $37K | |
| ||||||
 Ali Behbahani | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Rachel Meyers | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Nessan Bermingham | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Katharine Knobil | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Jean Francois Formela | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Timothy R. Pearson | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Ram Aiyar - Officer | Open-market sale | Common Stock | 15,152 | $12.98 footnote F2 | $197K | |
| ||||||
| Jean Francois Formela | Open-market sale | Common Stock | 2,441 | $13.95 | $34K | |
| Jean Francois Formela | Open-market sale | Common Stock | 419 | $13.95 | $6K | |
| Ram Aiyar - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $12.33 | $617K | |
| ||||||
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.001 par value per share | 520 | $10.60 | $6K | |
 Rick Yang | Open-market purchase | Common Stock | 207,100 | $11.11 | $2.30M | |
| Rick Yang | Open-market purchase | Pre-Funded Warrants | 242,945 | $11.11 | $2.70M | |
 Scott D. Sandell | Open-market purchase | Pre-Funded Warrants | 242,945 | $11.11 | $2.70M | |
| Scott D. Sandell | Open-market purchase | Common Stock | 207,100 | $11.11 | $2.30M | |
Item 8.01, 9.01
Item 8.01
Item 1.01, 2.02, 3.02, 9.01
Item 5.07
Recent KRRO Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Atlas Venture Opportunity Fund II, L.P. | Shareholder | 6,602 | $91K | View on EDGAR | |
| Atlas Venture Fund XI, L.P. | Shareholder | 31,888 |
KRRO insider trading FAQ
What is the latest insider trade for KRRO?
Korro Bio, Inc. (KRRO) had 12 insider filings in the last 90 days, with the most recent on 2026-09-15. The full record for KRRO runs to 50 Form 4 filings, the earliest from 2024-10-18. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying KRRO stock?
2 insider purchases of KRRO were filed in the last 90 days, totaling $79K.
How many insiders are selling KRRO stock?
14 insider sales of KRRO were filed in the last 90 days, totaling $1.28M.
Where can I see KRRO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects KRRO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jean Francois Formela view on EDGAR
- - Oliver Dolan view on EDGAR
- - Oliver Dolan view on EDGAR
- - Jean Francois Formela view on EDGAR
- - Jean Francois Formela view on EDGAR
- - Jean Francois Formela view on EDGAR
- - Lynx1 Capital Management LP view on EDGAR
- - Ram Aiyar view on EDGAR
- - Loic A. Vincent view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where KRRO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow KRRO with a 7-day demo
- KRRO on your watchlist
- Every KRRO Form 4 filing on record
- Up to 3 months of KRRO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
